Atlas Trials

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

Clinical trial NCT05818085 · COMPLETED

Trial details

NCT number
NCT05818085
Sponsor
Atom Therapeutics Co., Ltd
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Gout
Start date
2023-08-11
Primary completion
2025-01-30
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.